Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L de Ridder

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
The American Journal of Pathology|January 1, 1994
A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasionC R De Potter, A M Schelfhout, F H De Smet, et al.
Alimentary Pharmacology & Therapeutics|March 4, 2011
High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyZ Zelinkova, C de Haar, L de Ridder, et al.
Biochemical and Biophysical Research Communications|October 29, 1998
Cathepsin B-mediated activation of the proinflammatory caspase-11P Schotte, W Van Criekinge, M Van de Craen, et al.
European Journal of Nuclear Medicine|November 18, 1998
Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium)M Monsieurs, H Thierens, R A Dierckx, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2006
Pharmacogenetics of thiopurine therapy in paediatric IBD patientsL De Ridder, J M Van Dieren, H J H Van Deventer, et al.
Journal of Pediatric Gastroenterology and Nutrition|March 14, 2012
Rapid test for fecal calprotectin levels in children with Crohn diseaseK L Kolho, D Turner, G Veereman-Wauters, et al.
Clinical Pharmacokinetics|November 28, 2025
Correction: Population Pharmacokinetics Analysis of Infliximab in up to 10‑Year‑Old Patients with Paediatric Inflammatory Bowel Disease: Label‑Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Clinical Pharmacokinetics|October 29, 2025
Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Journal of Crohn'S & Colitis|March 12, 2014
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJ F Rahier, F Magro, C Abreu, et al.
Journal of Crohn'S & Colitis|March 17, 2021
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel DiseaseT Kucharzik, P Ellul, T Greuter, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
The American Journal of Pathology|January 1, 1994
A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasionC R De Potter, A M Schelfhout, F H De Smet, et al.
Alimentary Pharmacology & Therapeutics|March 4, 2011
High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyZ Zelinkova, C de Haar, L de Ridder, et al.
Biochemical and Biophysical Research Communications|October 29, 1998
Cathepsin B-mediated activation of the proinflammatory caspase-11P Schotte, W Van Criekinge, M Van de Craen, et al.
European Journal of Nuclear Medicine|November 18, 1998
Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium)M Monsieurs, H Thierens, R A Dierckx, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2006
Pharmacogenetics of thiopurine therapy in paediatric IBD patientsL De Ridder, J M Van Dieren, H J H Van Deventer, et al.
Journal of Pediatric Gastroenterology and Nutrition|March 14, 2012
Rapid test for fecal calprotectin levels in children with Crohn diseaseK L Kolho, D Turner, G Veereman-Wauters, et al.
Clinical Pharmacokinetics|November 28, 2025
Correction: Population Pharmacokinetics Analysis of Infliximab in up to 10‑Year‑Old Patients with Paediatric Inflammatory Bowel Disease: Label‑Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Clinical Pharmacokinetics|October 29, 2025
Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target ConcentrationQ Zhao, M M E Jongsma, S A Vuijk, et al.
Journal of Crohn'S & Colitis|March 12, 2014
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJ F Rahier, F Magro, C Abreu, et al.
Journal of Crohn'S & Colitis|March 17, 2021
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel DiseaseT Kucharzik, P Ellul, T Greuter, et al.
Pageof 16